Limits...
Development of Budesonide Loaded Biopolymer Based Dry Powder Inhaler: Optimization, In Vitro Deposition, and Cytotoxicity Study.

Mali AJ, Pawar AP, Purohit RN - J Pharm (Cairo) (2014)

Bottom Line: At same time, serious systemic side effects of drugs have become a cause for concern.The subject of present study, lactose-free budesonide loaded biopolymer based DPI, further corroborates the great potential of antiasthmatic drugs.This technology is expected to revolutionize the approaches towards enhanced therapeutic delivery of prospective drugs.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth University, Erandwane, Pune, Maharashtra 411038, India.

ABSTRACT
The progress in the development of DPI technology has boosted the use of sensitive drug molecules for lung diseases. However, delivery of these molecules from conventional DPI to the active site still poses a challenge with respect to deposition efficiency in the lung. At same time, serious systemic side effects of drugs have become a cause for concern. The developed budesonide loaded biopolymer based controlled release DPI had shown maximum in vitro lung deposition with least toxicity. The subject of present study, lactose-free budesonide loaded biopolymer based DPI, further corroborates the great potential of antiasthmatic drugs. This technology is expected to revolutionize the approaches towards enhanced therapeutic delivery of prospective drugs.

No MeSH data available.


Related in: MedlinePlus

(a) DSC plots and (b) PXRD plots of (A) budesonide, (B) formulated DPI, (C) chitosan, (D) sodium alginate, and (E) pluronic F-68.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4590799&req=5

fig5: (a) DSC plots and (b) PXRD plots of (A) budesonide, (B) formulated DPI, (C) chitosan, (D) sodium alginate, and (E) pluronic F-68.

Mentions: In Figure 5(a), DSC scan of budesonide showed sharp endothermic peak at 260°C due to melting transition point of drug. Chitosan exhibited endothermic peak at 104.93°C and exothermic peak at 265.30°C due to the melting and consequently degradation of polymer at higher temperature. DSC scan of sodium alginate showed broad endothermic peak at 105.69°C due to evaporation of water content. Pluronic F-68 showed endothermic peak at 35.20°C due to the melting of polymer. In the physical mixture endothermic peaks at 49.98°C, 118.70°C, and 309.34°C were observed. These peaks may be attributed to loss of water, interaction between the polymers, and melting of polymers at respective temperatures. The final formulation showed the endothermic peak at 81.05°C and exothermic peak at 260.29°C. These peaks mainly represent melting of polymer and degradation of system at higher temperature. The absence of endothermic peak of budesonide in the entire spectrum of formulation pointed out complete entrapment and reduction of drug crystallinity in polymer matrix [36].


Development of Budesonide Loaded Biopolymer Based Dry Powder Inhaler: Optimization, In Vitro Deposition, and Cytotoxicity Study.

Mali AJ, Pawar AP, Purohit RN - J Pharm (Cairo) (2014)

(a) DSC plots and (b) PXRD plots of (A) budesonide, (B) formulated DPI, (C) chitosan, (D) sodium alginate, and (E) pluronic F-68.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4590799&req=5

fig5: (a) DSC plots and (b) PXRD plots of (A) budesonide, (B) formulated DPI, (C) chitosan, (D) sodium alginate, and (E) pluronic F-68.
Mentions: In Figure 5(a), DSC scan of budesonide showed sharp endothermic peak at 260°C due to melting transition point of drug. Chitosan exhibited endothermic peak at 104.93°C and exothermic peak at 265.30°C due to the melting and consequently degradation of polymer at higher temperature. DSC scan of sodium alginate showed broad endothermic peak at 105.69°C due to evaporation of water content. Pluronic F-68 showed endothermic peak at 35.20°C due to the melting of polymer. In the physical mixture endothermic peaks at 49.98°C, 118.70°C, and 309.34°C were observed. These peaks may be attributed to loss of water, interaction between the polymers, and melting of polymers at respective temperatures. The final formulation showed the endothermic peak at 81.05°C and exothermic peak at 260.29°C. These peaks mainly represent melting of polymer and degradation of system at higher temperature. The absence of endothermic peak of budesonide in the entire spectrum of formulation pointed out complete entrapment and reduction of drug crystallinity in polymer matrix [36].

Bottom Line: At same time, serious systemic side effects of drugs have become a cause for concern.The subject of present study, lactose-free budesonide loaded biopolymer based DPI, further corroborates the great potential of antiasthmatic drugs.This technology is expected to revolutionize the approaches towards enhanced therapeutic delivery of prospective drugs.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth University, Erandwane, Pune, Maharashtra 411038, India.

ABSTRACT
The progress in the development of DPI technology has boosted the use of sensitive drug molecules for lung diseases. However, delivery of these molecules from conventional DPI to the active site still poses a challenge with respect to deposition efficiency in the lung. At same time, serious systemic side effects of drugs have become a cause for concern. The developed budesonide loaded biopolymer based controlled release DPI had shown maximum in vitro lung deposition with least toxicity. The subject of present study, lactose-free budesonide loaded biopolymer based DPI, further corroborates the great potential of antiasthmatic drugs. This technology is expected to revolutionize the approaches towards enhanced therapeutic delivery of prospective drugs.

No MeSH data available.


Related in: MedlinePlus